The development of Allogeneic Cell Therapies is vastly different than traditional biopharmaceutical products, including other cell and gene therapy products, and the complexities of this novel therapeutic treatment span the development pipeline.

With the increasing prevalence of allogeneic cell transplantation (allo-HCT), the importance of securing a cellular product safely from a donor, and ensuring that the product is without additional risk to the recipient, continues to be of critical importance.

Please join industry leaders from Eurofins VRL and Eurofins BioPharma Product Testing as we share our expertise in testing allo-HCT for routine collection and storage of cells for use in transplantation, immune therapies and other medically-validated indications.

During this webinar, our experts will discuss:

• Required testing for donor source cells: Infectious Disease
• Relevant donor source testing: Sterility, Endotoxin, Mycoplasma
• Determining Eligibility
• Post cell processing/manufacturing GMP biosafety testing
• The need to repeat the infectious disease testing
• Specialized testing based upon raw materials/reagents used in cell processing
• Relevant testing and why it is performed
• Technical and regulatory considerations

Presenters:

	Stanley Prince Senior Scientific Advisor, Biologics Eurofins BioPharma Product Testing
As a Senior Scientific Advisor for Eurofins BioPharma Product Testing, Mr. Prince provides technical and commercial support for GMP Biosafety services for large molecule and cell and gene therapy projects, helping clients to navigate specialized testing needs. Mr. Prince has worked for large molecule and cell and gene therapy CRO’s his entire career, bringing over 17 years of experience to his role at Eurofins. He earned a B.S. degree in life sciences from Penn State University and an M.B.A. from Alvernia University.
	Kimberly Elliott Director of Business Development Eurofins VRL
Kimberly Elliott is the Director of Business Development for Eurofins VRL. She brings over 20 years’ experience in the human cell and tissue industry. Ms. Elliot’s knowledge and expertise in Human Cells, Tissues, and Cellular and Tissue-Based Products(HCT/P) span regulated testing, business development, effective application of regulations and customer support for the recovery, testing and transplantation of organs, tissues, and tissue and cell-based products. Prior to joining Eurofins, Ms. Elliot has held leadership roles supporting HCT/P establishments in the tissue banking, cell therapy, and regenerative medicine space. Ms. Elliot is an active member of the American Association of Tissue Banks (AATB) and is currently the Co-Chair of the Program Committee. She is a graduate of Arizona State University with a B.S. in Exercise Physiology.